GWS
NVO

Greykasell Wealth Strategies’s Novo Nordisk NVO Stock Holding History

Greykasell Wealth Strategies’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.38K Sell
154
-2,115
-93% -$90.9K ﹤0.01% 402
2026
Q1 		$83.4K Hold
2,269
– – 0.03% 207
2025
Q4 		$115K Buy
2,269
+112
+5% +$5.73K 0.05% 177
2025
Q3 		$120K Hold
2,157
– – 0.05% 165
2025
Q2 		$149K Hold
2,157
– – 0.07% 144
2025
Q1 		$150K Buy
+2,157
New +$178K 0.08% 134

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Greykasell Wealth Strategies's NVO Position: Q2 2026 in Review

Greykasell Wealth Strategies reduced its Novo Nordisk (NVO) stake by 93% in Q2 2026, selling an estimated $90.9K and leaving 154 shares worth $7.38K. The position accounts for ﹤0.01% of the portfolio, ranked #402.

Greykasell Wealth Strategies first reported a position in NVO in Q1 2025 and has held it in 6 quarters since. The position peaked at $150K in Q1 2025. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Greykasell Wealth Strategies held 154 shares of Novo Nordisk worth $7.38K as of Q2 2026.
  • Greykasell Wealth Strategies sold 2,115 Novo Nordisk shares in Q2 2026, an estimated $90.9K.
  • Novo Nordisk made up ﹤0.01% of Greykasell Wealth Strategies's portfolio in Q2 2026, its #402 holding.
  • Greykasell Wealth Strategies first reported a position in Novo Nordisk in Q1 2025 and has held it in 6 quarters since.
  • Greykasell Wealth Strategies's Novo Nordisk position peaked at $150K in Q1 2025.
  • 1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q2 2026, filed 11 Aug 2026.